A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease
This retrospective study aimed to investigate the effect and safety of Yiqibushenhuoxue decoction (YQBSHXD) for the treatment of chronic obstructive pulmonary disease (COPD).This study involved 120 cases of patients with COPD. These cases were assigned to an intervention group and a control group equally, 60 subjects each group. Patients in both groups underwent Salmeterol. In addition, the cases in the intervention group also received YQBSHXD. All cases received a total of 12 weeks treatment. The primary outcome of lung function was measured by forced expiratory volume in 1 second (FEV1), and FEV1/forced vital capacity (FVC). The secondary outcomes included severity of dyspnea on exertion, evaluated by 6-minute walk test (6MWT) with measurement of 6-minute walk distance (6MWD); and quality of life, assessed by the St. George's Respiratory Questionnaire (SGRQ). In addition, adverse events (AEs) were also recorded in this study. All outcome measurements were assessed before and after 12-week treatment.After 12-week treatment, cases in the intervention group underwent YQBSHXD did not show better outcome in lung function improvement, measured by the FEV1 (P = .11), and FEV1/FVC (P = .15), compared with those in the control group. However, YQBSHXD may help to alleviate the severity of dyspnea on exertion, as measured by 6MWD (P = .03), and to improve the quality of life, as assessed by the SGRQ (P < .01). Additionally, no significant differences in AEs were detected between the 2 groups.The results of this study showed that YQBSHXD may help to manage COPD after 12-week treatment, although the lung function has not been improved.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
---|---|
Enthalten in: |
Medicine - 97(2018), 31 vom: 20. Aug., Seite e11684 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Zhuying [VerfasserIn] |
---|
Links: |
---|
Themen: |
6EW8Q962A5 |
---|
Anmerkungen: |
Date Completed 10.08.2018 Date Revised 28.09.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/MD.0000000000011684 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM287151352 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM287151352 | ||
003 | DE-627 | ||
005 | 20231225053356.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/MD.0000000000011684 |2 doi | |
028 | 5 | 2 | |a pubmed24n0957.xml |
035 | |a (DE-627)NLM287151352 | ||
035 | |a (NLM)30075564 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Zhuying |e verfasserin |4 aut | |
245 | 1 | 2 | |a A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.08.2018 | ||
500 | |a Date Revised 28.09.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a This retrospective study aimed to investigate the effect and safety of Yiqibushenhuoxue decoction (YQBSHXD) for the treatment of chronic obstructive pulmonary disease (COPD).This study involved 120 cases of patients with COPD. These cases were assigned to an intervention group and a control group equally, 60 subjects each group. Patients in both groups underwent Salmeterol. In addition, the cases in the intervention group also received YQBSHXD. All cases received a total of 12 weeks treatment. The primary outcome of lung function was measured by forced expiratory volume in 1 second (FEV1), and FEV1/forced vital capacity (FVC). The secondary outcomes included severity of dyspnea on exertion, evaluated by 6-minute walk test (6MWT) with measurement of 6-minute walk distance (6MWD); and quality of life, assessed by the St. George's Respiratory Questionnaire (SGRQ). In addition, adverse events (AEs) were also recorded in this study. All outcome measurements were assessed before and after 12-week treatment.After 12-week treatment, cases in the intervention group underwent YQBSHXD did not show better outcome in lung function improvement, measured by the FEV1 (P = .11), and FEV1/FVC (P = .15), compared with those in the control group. However, YQBSHXD may help to alleviate the severity of dyspnea on exertion, as measured by 6MWD (P = .03), and to improve the quality of life, as assessed by the SGRQ (P < .01). Additionally, no significant differences in AEs were detected between the 2 groups.The results of this study showed that YQBSHXD may help to manage COPD after 12-week treatment, although the lung function has not been improved | ||
650 | 4 | |a Evaluation Study | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Bronchodilator Agents |2 NLM | |
650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
650 | 7 | |a Salmeterol Xinafoate |2 NLM | |
650 | 7 | |a 6EW8Q962A5 |2 NLM | |
700 | 1 | |a Tian, Chunyan |e verfasserin |4 aut | |
700 | 1 | |a Wang, Xuehui |e verfasserin |4 aut | |
700 | 1 | |a Wang, Liqin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 97(2018), 31 vom: 20. Aug., Seite e11684 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
773 | 1 | 8 | |g volume:97 |g year:2018 |g number:31 |g day:20 |g month:08 |g pages:e11684 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000011684 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 97 |j 2018 |e 31 |b 20 |c 08 |h e11684 |